Literature DB >> 32546583

Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016.

Brian Rha1, Aaron T Curns2, Joana Y Lively2,3, Angela P Campbell4, Janet A Englund5, Julie A Boom6,7, Parvin H Azimi8, Geoffrey A Weinberg9, Mary A Staat10, Rangaraj Selvarangan11, Natasha B Halasa12, Monica M McNeal10, Eileen J Klein5, Christopher J Harrison11, John V Williams13, Peter G Szilagyi14, Monica N Singer8, Leila C Sahni6, Daniella Figueroa-Downing2,15, Darius McDaniel2,16, Mila M Prill2, Brett L Whitaker2, Laura S Stewart12, Jennifer E Schuster11, Barbara A Pahud11, Gina Weddle11, Vasanthi Avadhanula17, Flor M Munoz6,7,17, Pedro A Piedra6,7,17, Daniel C Payne2, Gayle Langley2, Susan I Gerber2.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of hospitalized acute respiratory illness (ARI) among young children. With RSV vaccines and immunoprophylaxis agents in clinical development, we sought to update estimates of US pediatric RSV hospitalization burden.
METHODS: Children <5 years old hospitalized for ARI were enrolled through active, prospective, population-based surveillance from November 1, 2015, to June 30, 2016, at 7 US pediatric hospital sites. Clinical information was obtained from parent interviews and medical records. Midturbinate nasal and throat flocked swabs were collected and tested for RSV by using molecular diagnostic assays at each site. We conducted descriptive analyses and calculated population-based rates of RSV-associated hospitalizations.
RESULTS: Among 2969 hospitalized children included in analyses, 1043 (35%) tested RSV-positive; 903 (87%) children who were RSV-positive were <2 years old, and 526 (50%) were <6 months old. RSV-associated hospitalization rates were 2.9 per 1000 children <5 years old and 14.7 per 1000 children <6 months old; the highest age-specific rate was observed in 1-month-old infants (25.1 per 1000). Most children who were infected with RSV (67%) had no underlying comorbid conditions and no history of preterm birth.
CONCLUSIONS: During the 2015-2016 season, RSV infection was associated with one-third of ARI hospitalizations in our study population of young children. Hospitalization rates were highest in infants <6 months. Most children who were RSV-positive had no history of prematurity or underlying medical conditions, suggesting that all young children could benefit from targeted interventions against RSV.
Copyright © 2020 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2020        PMID: 32546583     DOI: 10.1542/peds.2019-3611

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  35 in total

1.  Epidemiology of respiratory syncytial virus in a community birth cohort of infants in the first 2 years of life.

Authors:  Mari D Takashima; Keith Grimwood; Peter D Sly; Stephen B Lambert; Keith J Chappell; Daniel Watterson; Robert S Ware
Journal:  Eur J Pediatr       Date:  2021-02-25       Impact factor: 3.183

2.  4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication.

Authors:  Julien Sourimant; Carolin M Lieber; Megha Aggarwal; Robert M Cox; Josef D Wolf; Jeong-Joong Yoon; Mart Toots; Chengin Ye; Zachary Sticher; Alexander A Kolykhalov; Luis Martinez-Sobrido; Gregory R Bluemling; Michael G Natchus; George R Painter; Richard K Plemper
Journal:  Science       Date:  2021-12-02       Impact factor: 63.714

Review 3.  Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper.

Authors:  Susanna Esposito; Bahaa Abu-Raya; Paolo Bonanni; Fabianne Cahn-Sellem; Katie L Flanagan; Federico Martinon Torres; Asuncion Mejias; Simon Nadel; Marco A P Safadi; Arne Simon
Journal:  Front Immunol       Date:  2021-08-11       Impact factor: 7.561

4.  Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study.

Authors:  Zaid Haddadin; Jennifer E Schuster; Andrew J Spieker; Herdi Rahman; Anna Blozinski; Laura Stewart; Angela P Campbell; Joana Y Lively; Marian G Michaels; John V Williams; Julie A Boom; Leila C Sahni; Mary Staat; Monica McNeal; Rangaraj Selvarangan; Christopher J Harrison; Geoffrey A Weinberg; Peter G Szilagyi; Janet A Englund; Eileen J Klein; Aaron T Curns; Brian Rha; Gayle E Langley; Aron J Hall; Manish M Patel; Natasha B Halasa
Journal:  Pediatrics       Date:  2021-05-13       Impact factor: 7.124

5.  Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19.

Authors:  Laura A Vella; Josephine R Giles; Amy E Baxter; Derek A Oldridge; Caroline Diorio; Leticia Kuri-Cervantes; Cécile Alanio; M Betina Pampena; Jennifer E Wu; Zeyu Chen; Yinghui Jane Huang; Elizabeth M Anderson; Sigrid Gouma; Kevin O McNerney; Julie Chase; Chakkapong Burudpakdee; Jessica H Lee; Sokratis A Apostolidis; Alexander C Huang; Divij Mathew; Oliva Kuthuru; Eileen C Goodwin; Madison E Weirick; Marcus J Bolton; Claudia P Arevalo; Andre Ramos; C J Jasen; Peyton E Conrey; Samir Sayed; Heather M Giannini; Kurt D'Andrea; Nuala J Meyer; Edward M Behrens; Hamid Bassiri; Scott E Hensley; Sarah E Henrickson; David T Teachey; Michael R Betts; E John Wherry
Journal:  Sci Immunol       Date:  2021-03-02

Review 6.  Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.

Authors:  Ahmed Elkashif; Marwa Alhashimi; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Clin Transl Immunology       Date:  2021-10-12

7.  Role of age and birth month in infants hospitalized with RSV-confirmed disease in the Valencia Region, Spain.

Authors:  Ainara Mira-Iglesias; Clarisse Demont; F Xavier López-Labrador; Beatriz Mengual-Chuliá; Javier García-Rubio; Mario Carballido-Fernández; Miguel Tortajada-Girbés; Juan Mollar-Maseres; Germán Schwarz-Chavarri; Joan Puig-Barberà; Javier Díez-Domingo
Journal:  Influenza Other Respir Viruses       Date:  2021-11-24       Impact factor: 4.380

8.  Influenza clinical testing and oseltamivir treatment in hospitalized children with acute respiratory illness, 2015-2016.

Authors:  Lubna Hamdan; Varvara Probst; Zaid Haddadin; Herdi Rahman; Andrew J Spieker; Simon Vandekar; Laura S Stewart; John V Williams; Julie A Boom; Flor Munoz; Janet A Englund; Rangaraj Selvarangan; Mary A Staat; Geoffrey A Weinberg; Parvin H Azimi; Eileen J Klein; Monica McNeal; Leila C Sahni; Monica N Singer; Peter G Szilagyi; Christopher J Harrison; Manish Patel; Angela P Campbell; Natasha B Halasa
Journal:  Influenza Other Respir Viruses       Date:  2021-10-26       Impact factor: 4.380

9.  Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January - September 2020: Analysis of national surveillance data.

Authors:  Djin-Ye Oh; Silke Buda; Barbara Biere; Janine Reiche; Frank Schlosser; Susanne Duwe; Marianne Wedde; Max von Kleist; Martin Mielke; Thorsten Wolff; Ralf Dürrwald
Journal:  Lancet Reg Health Eur       Date:  2021-06-07

10.  Incidence and risk factors of hospitalisations for respiratory syncytial virus among children aged less than 2 years.

Authors:  Wasef Na'amnih; Eias Kassem; Shebly Tannous; Viktoria Kagan; Athar Jbali; Elizabeth Hanukayev; Sarit Freimann; Uri Obolski; Khitam Muhsen
Journal:  Epidemiol Infect       Date:  2022-02-02       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.